Inspire Medical Systems (INSP) News Today

Inspire Medical Systems, Inc. (NYSE: INSP) shares have decreased after a strong recent rally, as investors weigh the company’s improved outlook against continuing reimbursement and procedure-volume concerns.

• Positive Sentiment: Q2 results exceeded expectations. Inspire reported adjusted earnings of $0.14 per share versus the consensus estimate for a $0.24 loss, while revenue of $200.6 million surpassed estimates of $194.7 million. The earnings beat helped support the recent rally. Inspire Medical Q2 Earnings Beat Estimates, 2026 View Raised, Stock Up
• Positive Sentiment: Management raised fiscal 2026 guidance. EPS guidance is now $1.05-$1.45, above the roughly $0.91 analyst consensus, with revenue projected at $835 million-$875 million. Improved product mix, including Inspire V, and cost controls are helping offset softer U.S. procedure activity. INSP Raises 2026 Outlook as Reimbursement Headwinds Start to Ease
• Positive Sentiment: Analyst sentiment improved. Oppenheimer upgraded INSP to outperform with an $85 price target, and Mizuho raised its target to $65 while maintaining an outperform rating. These revisions reflect greater confidence in earnings and margin improvement. Inspire Medical Systems Analysts Raise Their Forecasts
• Neutral Sentiment: Valuation and long-term opportunity remain debated. The company has a debt-free balance sheet, improving margins and a sizable sleep-apnea market opportunity. However, after a 28.1% one-month gain, some of the favorable Q2 news may already be reflected in the stock. INSP’s 28.1% Past-Month Rally
• Negative Sentiment: Reimbursement remains the primary risk. Revenue declined 7.6% year over year, and weaker U.S. procedure activity continues to pressure near-term growth. JPMorgan and Baird raised their price targets but retained neutral ratings, indicating limited near-term upside at recent trading levels. Is INSP a Buy as Margins Improve but Reimbursement Risks Persist?